Myriad Genetics and Pfizer make laboratory agreement
Myriad Genetics, Inc. (MYGN) is up 7.7% Wednesday morning. The company has entered into an agreement with drug maker Pfizer (PFE) to run tests on a treatment for breast cancer.
Myriad Genetics, Inc. (MYGN) is a diagnostics and research company.
Esterline Technologies Corporation (ESL) and Potbelly Corporation (PBPB) top the list of other companies with positive news today, while Trinseo S.A. (TSE) and Tiffany & Co. (TIF) top the list of companies with negative news.
Already a member?
Login to see your Morning News Leader Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease or tailor treatment for already diagnosed patients. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysis CDx, GeneSight, Vectra DA, and Prolaris. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.